Frankfurt
21.02.25
08:05 Uhr
0,117 Euro
+0,022
+23,67 %
+23,67 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | AlzeCure Pharma: AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease | 200 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for... ► Artikel lesen | |
| 21.01. | AlzeCure's NeuroRestore ACD856 to be presented at AD/PD 2025 | 2 | PharmaTimes | ||
| 21.01. | AlzeCure Pharma: AlzeCure Receives Abstract Acceptance at Alzheimer's Congress AD/PD 2025 on NeuroRestore ACD856 | 274 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / January 21, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 27.11.24 | AlzeCure Pharma: AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm | 272 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drugs for... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 26.11.24 | AlzeCure Pharma to Present at Redeye Life Science Day on December 3 | 251 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 26, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 20.11.24 | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm | 340 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 11.11.24 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2024 | 670 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September... ► Artikel lesen | |
| 30.10.24 | AlzeCure Pharma: AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD | 440 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 30, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 28.10.24 | AlzeCure Pharma: AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis | 246 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 24.10.24 | AlzeCure Pharma: AlzeCure to Present at the International Partnering Conference Bioscience 2024 on November 7 | 318 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 24, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 17.10.24 | AlzeCure Pharma's CEO Martin Jönsson to present at Redeye's Neurology Day | 246 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 17, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 10.10.24 | AlzeCure Pharma Broadcasts Live Event About the Phase II Candidate ACD440 Against Neuropathic Pain | 282 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 10, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.10.24 | AlzeCure's abstract on ACD856's effects to be presented at Alzheimer's conference | 5 | PharmaTimes | ||
| 01.10.24 | AlzeCure Pharma: AlzeCure's Abstract on ACD856's Anti-inflammatory Effects to be Presented at a Leading Alzheimer's Conference | 287 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / October 1, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 26.08.24 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2024 | 492 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / August 26, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June... ► Artikel lesen | |
| 13.08.24 | AlzeCure Pharma: New Scientific Article on NeuroRestore ACD856 and its Improved Cognition and Disease Modification of Alzheimer's Disease | 721 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / August 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 07.08.24 | AlzeCure Pharma: New Results from AlzeCure's Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024 | 300 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 13.06.24 | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 396 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / June 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 28.05.24 | Nasdaq Stockholm AB: New last day of trading in paid subscription shares (BTA) of AlzeCure Pharma AB (publ) | 249 | GlobeNewswire | At the request of AlzeCure Pharma AB (publ), the last trading day in AlzeCure
Pharma AB (publ)'s paid subscription units will be changed from May 30, 2024 to
May 31, 2024.
Short name: ALZCUR BTA... ► Artikel lesen | |
| 15.05.24 | AlzeCure Pharma: Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member | 624 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's... ► Artikel lesen |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 465,50 | +0,52 % | Analyst Expectations For Vertex Pharmaceuticals' Future | ||
| VIATRIS | 10,795 | +0,33 % | Viatris: Uniting Against AMR: Global Solutions Need Local and Global Collaboration | NORTHAMPTON, MA / ACCESS Newswire / February 19, 2025 / By: James Headen Pfitzer, Senior Director, Global Policy, Corporate Affairs, Viatris and Melissa Mitchell, AMR IA Secretariat LeadOur world is... ► Artikel lesen | |
| OPKO HEALTH | 1,627 | +1,61 % | OPKO Health, Inc.: ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program | Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment... ► Artikel lesen | |
| JAGUAR HEALTH | 0,855 | -2,98 % | Jaguar Health, Inc.: Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure | This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications... ► Artikel lesen | |
| ALTIMMUNE | 6,088 | -0,73 % | Altimmune, Inc: Altimmune Added to Nasdaq Biotechnology Index | GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,226 | +1,32 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL | - Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 7,482 | -1,24 % | Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development | ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 3,470 | -1,14 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 | Encinitas, California--(Newsfile Corp. - February 13, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter... ► Artikel lesen | |
| PHOTOCURE | 4,320 | -0,58 % | Photocure ASA: Results for the fourth quarter of 2024 | OSLO, Norway, Feb. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million)... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 2,209 | 0,00 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates... ► Artikel lesen | |
| LIPOCINE | 3,440 | -1,71 % | Lipocine Inc.: FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis | SALT LAKE CITY, Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 25,200 | 0,00 % | Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners | Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners Paris... ► Artikel lesen | |
| MEDICURE | 0,418 | 0,00 % | Medicure, Inc.: Medicure Announces Expansion of Its Pharmacy Business Through Signing of a Purchase Agreement for the Acquisition of Gateway Medical Pharmacy | WINNIPEG, MB / ACCESS Newswire / February 18, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 22,050 | +1,73 % | Bayer-Aktie: Kunst unterm Hammer, Milliarden-Schulden und ein wackliger Aufwärtstrend. Lohnt sich ein Einstieg wirklich? | © Foto: Bayer AGBayer sorgt mal wieder für Gesprächsstoff. Diesmal nicht mit Klagen oder Glyphosat-Schlagzeilen, sondern mit einem riesigen Kunstverkauf. Der Konzern will rund 800 Kunstwerke versteigern... ► Artikel lesen | |
| MERCK KGAA | 135,50 | -0,70 % | Merck KGaA Aktie: Erfolgswelle setzt Segel! | Die Merck-Aktie verzeichnet heute einen leichten Kursrückgang im XETRA-Handel. Das Wertpapier des Darmstädter Konzerns bewegte sich am Vormittag abwärts und notierte bei 135,30 Euro, was einem Minus... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +23,67 % bei einem Aktienkurs von 0,117 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.
